Prexige Review Will Not Include FDA Arthritis Drugs Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis expects action later this year on lumiracoxib after resubmitting the application, the company tells “The Pink Sheet” DAILY.